0000886163-19-000090.txt : 20190531 0000886163-19-000090.hdr.sgml : 20190531 20190531182711 ACCESSION NUMBER: 0000886163-19-000090 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190529 FILED AS OF DATE: 20190531 DATE AS OF CHANGE: 20190531 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Aryeh Jason CENTRAL INDEX KEY: 0001376960 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 19871721 MAIL ADDRESS: STREET 1: 11119 NORTH TORREY PINES ROAD STREET 2: SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2019-05-29 0 0000886163 LIGAND PHARMACEUTICALS INC LGND 0001376960 Aryeh Jason 3911 SORRENTO VALLEY BOULEVARD, STE 110 SAN DIEGO CA 92121 1 0 0 0 Common Stock 2019-05-29 4 P 0 250 111.01 A 59868 D Common Stock 2019-05-30 4 P 0 250 110.01 A 60118 D Common Stock 2019-05-31 4 P 0 500 108.51 A 60618 D Common Stock 51594 I Indirect Common Stock 5025 I by Trust The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $108.01 to $109.01, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds. By: Charles S. Berkman For: Jason Aryeh 2019-05-31